查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2047048

家庭藥物濫用檢測市場－全球產業規模、佔有率、趨勢、機會、預測：按樣本類型、產品類型、地區和競爭格局分類，2021-2031年

At-Home Drug of Abuse Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sample Type, By Product Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球家用藥物濫用檢測市場預計將從 2025 年的 7.8072 億美元大幅成長至 2031 年的 12.1636 億美元，複合年成長率為 7.67%。

該市場提供診斷解決方案，使用戶能夠在私密的家中，利用尿液、唾液和毛髮等生物特徵樣本篩檢非法藥物和處方藥。推動這一市場成長的關鍵因素包括：消費者對隱私的強烈需求、無需預約即可快速獲得檢測結果的便利性，以及日益普遍的藥物濫用障礙需要定期監測。例如，美國國家安全委員會的報告指出，2023年美國將有97,231例可預防的藥物過量死亡，凸顯了對便捷易用的檢測方法的迫切需求，而這正是推動市場需求的關鍵所在。

市場概覽
預測期 2027-2031
市場規模：2025年 7.8072億美元
市場規模：2031年 1,216,360,000 美元
複合年成長率：2026-2031年 7.67%
成長最快的細分市場 驗血
最大的市場 北美洲

儘管存在這些有利的成長要素，但市場擴張仍面臨許多重大障礙，例如人們對檢體完整性的持續擔憂，以及與受控的實驗室篩檢相比，非監督式檢測準確性較低的問題。檢體採集過程中缺乏專家監督，有檢體被竄改和操縱的風險，可能影響檢測結果的可靠性。這項限制限制了家用檢測試劑盒在公共或法律診斷應用中的適用性，阻礙了其在市場上的廣泛普及。

市場促進因素

全球藥物濫用和鴉片類藥物成癮的日益普遍是推動居家檢測市場發展的主要動力，也因此對頻繁且保密的篩檢方法產生了顯著需求。成癮危機的廣泛影響使得居家診斷工具成為預防嚴重健康後果的關鍵第一道防線。根據美國藥物濫用和精神健康服務管理局 (SAMHSA) 發布的《2024 年全國藥物濫用與健康調查報告》（2025 年 11 月），到 2024 年，約有 4840 萬 12 歲及以上的美國人符合藥物濫用障礙的診斷標準。這一普遍存在的問題導致人們對便捷的監測工具的需求持續成長，而美國疾病管制與預防中心 (CDC) 的中期數據顯示，2024 年美國預計將有 80391 人死於藥物過量，進一步凸顯了這一需求。這強調了早期發現的重要性。

此外，快速檢測靈敏度和易用性的提升，使得即使是未經專業訓練的人員也能進行複雜的診斷，從而擴大了市場。製造商正積極開發非侵入性檢測方案，例如唾液檢測套組，與傳統的尿液檢查相比，這些方案簡化了檢體採集過程，同時保持了快速出結果的能力。例如，美國篩檢公司（American Screening Corp.）在2025年12月的MEDICA展覽會上推出了一款新型唾液藥物檢測套組，據稱只需兩分鐘即可出結果。這些在速度和易用性方面的創新直接回應了消費者的關切，並推動了居家檢測在個人安全和主動健康管理方面的普及。

市場挑戰

全球家用毒品檢測市場擴張的主要障礙在於人們對檢體完整性的持續擔憂，以及與檢查室篩檢相比，非監督式檢測方法固有的準確性較低。由於這些診斷工具在缺乏專家監督的私人場所使用，因此檢體被篡改、替換或處理不當的風險要高得多。由於缺乏檢驗的儲存和控制鏈，家用檢測檢測套組幾乎無法用於關鍵的公共應用，例如入職前篩檢、法律訴訟或法院強制監測，因此，市場成長主要局限於個人使用和資訊收集領域。

加劇這項挑戰的還有快速篩檢技術靈敏度的技術局限性，這些技術通常被整合到這些試劑盒中。 2025 年 ADLM 年度科學會議上發表的一項研究表明，由於靈敏度閾值問題，標準尿液藥物篩檢免疫檢測在某些病患小組中約有 5% 的檢體未能檢測到目標物質。這些數據凸顯了即使在規範的臨床環境中也可能出現假陰性結果。在缺乏監管的住宅環境中，使用者操作失誤的可能性更大，且無法進行確認性檢測，這種可靠性差距對機構買家構成重大障礙，並直接阻礙了家用解決方案的商業性化應用。

市場趨勢

市場的一個關鍵趨勢是開發專門用於檢測合成鴉片類藥物和Fentanyl的多聯檢測試劑盒。這促使製造商調整其產品線，以應對高致命性合成雜質的廣泛出現。由於傳統的篩檢試劑盒已無法滿足需求，因此對能夠識別Fentanyl和賽拉嗪等強效物質的專用試紙的需求日益成長。這一發展趨勢主要受減少危害措施的推動，這些措施優先考慮檢測特定雜質，以防止致命的過量用藥。例如，2025年4月的報告顯示，費城衛生局在2023年分發了超過18萬張Fentanyl試紙和近5萬張賽拉嗪試紙，凸顯了對這類標靶診斷設備的迫切需求。

另一個重要趨勢是將居家檢測整合到遠端醫療和遠距復健計畫中，這標誌著醫療模式正在發生結構性轉變，即轉向在住宅環境中使用數位監測診斷。隨著虛擬醫療模式的不斷發展，醫療服務提供者越來越依賴遠端檢驗工具來監測患者的戒酒戒毒情況，而無需患者親自前往診所。這種整合為與數位化報告平台相容的檢測套組創造了一個穩定的市場。根據美國藥物濫用和精神健康服務管理局 (SAMHSA) 發布的《2024 年全國藥物使用與健康調查》（2025 年 11 月），2024 年約有 360 萬人接受了遠端醫療藥物濫用治療，這表明遠距離診斷解決方案擁有龐大的使用者群體。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球家用藥物濫用檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 檢體類型（尿液檢查、唾液檢測、血液檢測、其他）
    • 產品類型（藥物檢測套組、試紙/浸入式檢測卡、卡式檢測盒、檢測杯、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美家庭藥物濫用檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲家庭藥物濫用檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區家庭藥物濫用檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲家庭藥物濫用檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲家庭藥物濫用檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球家用藥物濫用檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories, Inc.
  • Quest Diagnostics Incorporated
  • LabCorp（Laboratory Corporation of America Holdings）
  • Alere Inc.（now part of Abbott）
  • OraSure Technologies, Inc.
  • TruMed Systems, Inc.
  • Thermo Fisher Scientific Inc.
  • Premier Biotech, Inc.
  • Alkaway Systems
  • Instant Technologies, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17177

The global at-home drug of abuse testing market is projected to expand significantly, growing from USD 780.72 million in 2025 to USD 1216.36 million by 2031, at a compound annual growth rate (CAGR) of 7.67%. This market offers diagnostic solutions that empower individuals to screen for illicit or prescribed substances using biological samples like urine, saliva, or hair within the privacy of their homes. Key drivers for this growth include a strong consumer preference for confidentiality, the convenience of receiving rapid results without needing a clinical appointment, and the escalating prevalence of substance use disorders, which demand regular monitoring. For instance, the National Safety Council reported 97,231 preventable drug overdose deaths in the United States in 2023, underscoring the urgent need for accessible detection methods that fuels market demand.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 780.72 Million
Market Size 2031USD 1216.36 Million
CAGR 2026-20317.67%
Fastest Growing SegmentBlood test
Largest MarketNorth America

Despite these favorable growth drivers, a notable hurdle for market expansion is the ongoing concern about sample integrity and the diminished accuracy of unsupervised tests when compared to controlled laboratory-based screenings. The absence of professional supervision during sample collection introduces a risk of adulteration or tampering, which can compromise the reliability of test outcomes. This limitation restricts the suitability of at-home kits for official or legal diagnostic applications, thereby hindering broader market utility.

Market Driver

The escalating global prevalence of substance abuse and opioid addiction is a principal catalyst propelling the at-home testing market, creating a significant need for frequent and confidential screening methods. The extensive scope of the addiction crisis has made at-home diagnostic tools an essential first line of defense against severe health consequences. Data from SAMHSA's '2024 National Survey on Drug Use and Health' (November 2025) indicates that roughly 48.4 million Americans aged 12 and above met criteria for a substance use disorder in 2024. This widespread problem generates ongoing demand for accessible monitoring, a need further emphasized by the severe outcomes, such as the estimated 80,391 drug overdose deaths in the U.S. during 2024, as provisional data from the CDC (May 2025) suggests, highlighting the crucial importance of early detection.

Furthermore, advancements in rapid test sensitivity and user-friendliness are expanding the market by making intricate diagnostics feasible for individuals without professional training. Manufacturers are actively developing non-invasive testing solutions, like saliva-based kits, which simplify the collection process compared to traditional urine methods while maintaining high-speed results. For example, American Screening Corp unveiled a new saliva drug test at the MEDICA trade fair in December 2025, reportedly capable of providing results in just two minutes. These innovations in speed and ease of use directly address consumer concerns, fostering broader adoption of at-home testing for personal safety and proactive health management.

Market Challenge

The primary obstacle impeding the expansion of the global at-home drug of abuse testing market is the persistent worry concerning sample integrity and the inherently lower accuracy of unsupervised testing methods compared to laboratory-based screenings. Since these diagnostic tools are used in private settings without professional supervision, there is a considerable risk of specimen adulteration, substitution, or tampering. This absence of a verifiable chain of custody effectively precludes at-home kits from being utilized for critical official purposes, such as pre-employment screenings, legal processes, or court-ordered monitoring, thereby largely confining the market's growth to personal or informational applications.

Compounding this challenge is the technical constraint related to the sensitivity of rapid screening technologies commonly integrated into these kits. Research presented at the ADLM annual scientific meeting in 2025 showed that standard urine drug screening immunoassays failed to detect targeted substances in approximately 5% of samples within specific patient groups, due to sensitivity thresholds. This data underscores the potential for false negatives even in regulated clinical environments; in an unsupervised residential setting, where user error is more probable and confirmatory testing is unavailable, this reliability gap serves as a significant deterrent for institutional purchasers, directly hindering the widespread commercial acceptance of at-home solutions.

Market Trends

A key market trend involves the creation of multi-panel kits specifically designed for detecting synthetic opioids and fentanyl, prompting manufacturers to adjust their product offerings in response to the widespread emergence of highly lethal synthetic adulterants. Traditional screening panels are proving increasingly inadequate, driving a demand for specialized test strips capable of identifying potent substances such as fentanyl and xylazine. This evolution is largely fueled by harm reduction initiatives that prioritize the detection of specific adulterants to avert fatal overdoses. For instance, in 2023, the City of Philadelphia's Health Department distributed over 180,000 fentanyl test strips and nearly 50,000 xylazine test strips, as reported in April 2025, highlighting the crucial need for these targeted diagnostic instruments.

Another significant trend is the integration of at-home testing into telehealth and remote recovery programs, signifying a structural shift towards digitally monitored diagnostic use in residential settings. As virtual care models continue to develop, healthcare providers are increasingly relying on remote verification tools to monitor patient sobriety without requiring in-person clinic visits. This integration cultivates a consistent market for testing kits that are compatible with digital reporting platforms. SAMHSA's '2024 National Survey on Drug Use and Health' (November 2025) revealed that approximately 3.6 million individuals received telehealth treatment for substance use in 2024, indicating a substantial user base for remote diagnostic solutions.

Key Market Players

  • Abbott Laboratories, Inc.
  • Quest Diagnostics Incorporated
  • LabCorp (Laboratory Corporation of America Holdings)
  • Alere Inc. (now part of Abbott)
  • OraSure Technologies, Inc.
  • TruMed Systems, Inc.
  • Thermo Fisher Scientific Inc.
  • Premier Biotech, Inc.
  • Alkaway Systems
  • Instant Technologies, Inc.

Report Scope

In this report, the Global At-Home Drug of Abuse Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

At-Home Drug of Abuse Testing Market, By Sample Type

  • Urine Test
  • Saliva Test
  • Blood test
  • Others

At-Home Drug of Abuse Testing Market, By Product Type

  • Drug Testing Kit
  • Strips/Dip Cards
  • Cassettes
  • Cups
  • Others

At-Home Drug of Abuse Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global At-Home Drug of Abuse Testing Market.

Available Customizations:

Global At-Home Drug of Abuse Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global At-Home Drug of Abuse Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sample Type (Urine Test, Saliva Test, Blood test, Others)
    • 5.2.2. By Product Type (Drug Testing Kit, Strips/Dip Cards, Cassettes, Cups, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America At-Home Drug of Abuse Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sample Type
    • 6.2.2. By Product Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States At-Home Drug of Abuse Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sample Type
        • 6.3.1.2.2. By Product Type
    • 6.3.2. Canada At-Home Drug of Abuse Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sample Type
        • 6.3.2.2.2. By Product Type
    • 6.3.3. Mexico At-Home Drug of Abuse Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sample Type
        • 6.3.3.2.2. By Product Type

7. Europe At-Home Drug of Abuse Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sample Type
    • 7.2.2. By Product Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany At-Home Drug of Abuse Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sample Type
        • 7.3.1.2.2. By Product Type
    • 7.3.2. France At-Home Drug of Abuse Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sample Type
        • 7.3.2.2.2. By Product Type
    • 7.3.3. United Kingdom At-Home Drug of Abuse Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sample Type
        • 7.3.3.2.2. By Product Type
    • 7.3.4. Italy At-Home Drug of Abuse Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sample Type
        • 7.3.4.2.2. By Product Type
    • 7.3.5. Spain At-Home Drug of Abuse Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sample Type
        • 7.3.5.2.2. By Product Type

8. Asia Pacific At-Home Drug of Abuse Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sample Type
    • 8.2.2. By Product Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China At-Home Drug of Abuse Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sample Type
        • 8.3.1.2.2. By Product Type
    • 8.3.2. India At-Home Drug of Abuse Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sample Type
        • 8.3.2.2.2. By Product Type
    • 8.3.3. Japan At-Home Drug of Abuse Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sample Type
        • 8.3.3.2.2. By Product Type
    • 8.3.4. South Korea At-Home Drug of Abuse Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sample Type
        • 8.3.4.2.2. By Product Type
    • 8.3.5. Australia At-Home Drug of Abuse Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sample Type
        • 8.3.5.2.2. By Product Type

9. Middle East & Africa At-Home Drug of Abuse Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sample Type
    • 9.2.2. By Product Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia At-Home Drug of Abuse Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sample Type
        • 9.3.1.2.2. By Product Type
    • 9.3.2. UAE At-Home Drug of Abuse Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sample Type
        • 9.3.2.2.2. By Product Type
    • 9.3.3. South Africa At-Home Drug of Abuse Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sample Type
        • 9.3.3.2.2. By Product Type

10. South America At-Home Drug of Abuse Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sample Type
    • 10.2.2. By Product Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil At-Home Drug of Abuse Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sample Type
        • 10.3.1.2.2. By Product Type
    • 10.3.2. Colombia At-Home Drug of Abuse Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sample Type
        • 10.3.2.2.2. By Product Type
    • 10.3.3. Argentina At-Home Drug of Abuse Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sample Type
        • 10.3.3.2.2. By Product Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global At-Home Drug of Abuse Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Quest Diagnostics Incorporated
  • 15.3. LabCorp (Laboratory Corporation of America Holdings)
  • 15.4. Alere Inc. (now part of Abbott)
  • 15.5. OraSure Technologies, Inc.
  • 15.6. TruMed Systems, Inc.
  • 15.7. Thermo Fisher Scientific Inc.
  • 15.8. Premier Biotech, Inc.
  • 15.9. Alkaway Systems
  • 15.10. Instant Technologies, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer